Document is current
Any future updates will be listed below
-
Authors
Nørgaard, Jakob Nordberg http://orcid.org/0000-0002-8762-0530
Abildgaard, Niels
Lysén, Anna
Tsykunova, Galina
Vangsted, Annette Juul http://orcid.org/0000-0002-2131-731X
João, Cristina http://orcid.org/0000-0002-3978-766X
Remen, Nora
Nielsen, Lene Kongsgaard http://orcid.org/0000-0003-2083-3870
Osnes, Liv
Stokke, Caroline
Connelly, James P.
Revheim, Mona-Elisabeth R. http://orcid.org/0000-0003-3300-7420
,
Schjesvold, Fredrik http://orcid.org/0000-0003-1096-0569
-
Funding
Funding for this research was provided by:
KG Jebsen Center for B-cell Malignancies, University of Oslo
- License Information
-
More Information
Article History
Received: 2 May 2023
Revised: 26 July 2023
Accepted: 4 August 2023
First Online: 11 August 2023
Competing interests
: JNN has received honoraria from Janssen. NA has received research grants from Janssen, Celgene, BMS, Amgen, and Takeda. GT has received consultancy/honoraria from Amgen, Janssen, Ablynx, and Sobi, as well as research funding from Amgen. FS has received honoraria from Amgen, BMS, Abbvie, Janssen, and GSK. He has received grants from Amgen and Targovax and received compensation for adbords from GSK, Takeda, BMS, Janssen, Oncopeptides, Sanofi, and XNK therapeutics. The remaining authors declare no competing interests.
